BioCentury | Jan 13, 2018
Finance

Choosy investors

...Aviv:CLSN) 10/27/17 $6.6 $27.5 $43.0 57% Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) 10/27/17 $21.3 $105.0 $146.7 40% Atossa Genetics Inc....
BioCentury | May 5, 2017
Clinical News

Safety committee recommends continuation of Atossa's Ph I endoxifen trial

...a Phase II trial of endoxifen in 2H17. Endoxifen is an active metabolite of tamoxifen. Atossa Genetics Inc....
BioCentury | Apr 7, 2017
Finance

Taking notice

...NASDAQ:TNXP) 3/30/17 $8.0 $26.5 $27.8 5% Alliqua BioMedical Inc. (NASDAQ:ALQA) 3/29/17 $3.8 $18.2 $22.7 25% Atossa Genetics Inc....
BioCentury | Mar 31, 2017
Financial News

Atossa Genetics completes follow-on

...Drug delivery and cancer company Atossa Genetics Inc. (NASDAQ:ATOS) raised $4 million through the sale of 664,000 class...
...into 1,333 common shares, and five-year warrants to purchase up to 1,333 shares at $0.94. Atossa Genetics Inc....
BioCentury | Feb 17, 2017
Financial News

Atossa proposes follow-on

...On Feb. 13, drug delivery and cancer company Atossa Genetics Inc. (NASDAQ:ATOS) proposed to raise up to $4...
...NASDAQ:ATOS) proposed to raise up to $4 million in a follow-on underwritten by Aegis Capital. Atossa Genetics Inc....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...NASDAQ:SAGE) 9/8/16 $175.0 $1,450.7 $1,680.7 16% Xenon Pharmaceuticals Inc. (NASDAQ:XENE) 9/8/16 $25.9 $134.1 $141.2 5% Atossa Genetics Inc....
BioCentury | Sep 5, 2016
Financial News

Atossa Genetics completes follow-on

Atossa Genetics Inc. (NASDAQ:ATOS), Seattle, Wash. Business: Cancer Date completed: 2016-08-31 Type: Follow-on Raised: $2.9 million Shares: 1.2 million Price: $2.50 Shares after offering: 3.8 million Underwriter: Aegis Capital Overallotment: 172,500 WIR Staff...
BioCentury | May 30, 2016
Financial News

Atossa Genetics financial update

Atossa Genetics Inc. (NASDAQ:ATOS), Seattle, Wash. Business: Cancer Date announced: 2016-05-27 Note: Atossa entered into a 30-month stock purchase agreement with Aspire Capital for up to $10 million. WIR Staff cancer...
BioCentury | Mar 14, 2016
Clinical News

Intraductal fulvestrant: Phase II started

...to undergo a mastectomy. Faslodex is approved in the U.S. to treat metastatic breast cancer. Atossa Genetics Inc....
BioCentury | Jun 22, 2015
Company News

Besins Healthcare, Atossa Genetics deal

...active tamoxifen metabolite 4-hydroxytamoxifen, an estrogen receptor (ER) antagonist. Besins Healthcare S.A. , Bangkok, Thailand Atossa Genetics Inc....
Items per page:
1 - 10 of 59
BioCentury | Jan 13, 2018
Finance

Choosy investors

...Aviv:CLSN) 10/27/17 $6.6 $27.5 $43.0 57% Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) 10/27/17 $21.3 $105.0 $146.7 40% Atossa Genetics Inc....
BioCentury | May 5, 2017
Clinical News

Safety committee recommends continuation of Atossa's Ph I endoxifen trial

...a Phase II trial of endoxifen in 2H17. Endoxifen is an active metabolite of tamoxifen. Atossa Genetics Inc....
BioCentury | Apr 7, 2017
Finance

Taking notice

...NASDAQ:TNXP) 3/30/17 $8.0 $26.5 $27.8 5% Alliqua BioMedical Inc. (NASDAQ:ALQA) 3/29/17 $3.8 $18.2 $22.7 25% Atossa Genetics Inc....
BioCentury | Mar 31, 2017
Financial News

Atossa Genetics completes follow-on

...Drug delivery and cancer company Atossa Genetics Inc. (NASDAQ:ATOS) raised $4 million through the sale of 664,000 class...
...into 1,333 common shares, and five-year warrants to purchase up to 1,333 shares at $0.94. Atossa Genetics Inc....
BioCentury | Feb 17, 2017
Financial News

Atossa proposes follow-on

...On Feb. 13, drug delivery and cancer company Atossa Genetics Inc. (NASDAQ:ATOS) proposed to raise up to $4...
...NASDAQ:ATOS) proposed to raise up to $4 million in a follow-on underwritten by Aegis Capital. Atossa Genetics Inc....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...NASDAQ:SAGE) 9/8/16 $175.0 $1,450.7 $1,680.7 16% Xenon Pharmaceuticals Inc. (NASDAQ:XENE) 9/8/16 $25.9 $134.1 $141.2 5% Atossa Genetics Inc....
BioCentury | Sep 5, 2016
Financial News

Atossa Genetics completes follow-on

Atossa Genetics Inc. (NASDAQ:ATOS), Seattle, Wash. Business: Cancer Date completed: 2016-08-31 Type: Follow-on Raised: $2.9 million Shares: 1.2 million Price: $2.50 Shares after offering: 3.8 million Underwriter: Aegis Capital Overallotment: 172,500 WIR Staff...
BioCentury | May 30, 2016
Financial News

Atossa Genetics financial update

Atossa Genetics Inc. (NASDAQ:ATOS), Seattle, Wash. Business: Cancer Date announced: 2016-05-27 Note: Atossa entered into a 30-month stock purchase agreement with Aspire Capital for up to $10 million. WIR Staff cancer...
BioCentury | Mar 14, 2016
Clinical News

Intraductal fulvestrant: Phase II started

...to undergo a mastectomy. Faslodex is approved in the U.S. to treat metastatic breast cancer. Atossa Genetics Inc....
BioCentury | Jun 22, 2015
Company News

Besins Healthcare, Atossa Genetics deal

...active tamoxifen metabolite 4-hydroxytamoxifen, an estrogen receptor (ER) antagonist. Besins Healthcare S.A. , Bangkok, Thailand Atossa Genetics Inc....
Items per page:
1 - 10 of 59